Nektar Therapeutics announced amendments to its bylaws, including an increase in authorized common stock shares from 300 million to 390 million, effective June 6, 2025. Additionally, a reverse stock split at a ratio of one-for-fifteen will take effect on June 8, 2025, consolidating every fifteen shares into one. Trading on a split-adjusted basis will begin on June 9, 2025, under the existing symbol "NKTR" with a new CUSIP number.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-052141), on June 06, 2025, and is solely responsible for the information contained therein.